[ad_1] Shares of Granules India Ltd. climbed nearly 3% on monday hitting an intraday high of ₹474.74, after Life Insurance Corporation of India (LIC) increased its stake in the pharmaceutical company to 5.02%. PSU insurance giant, LIC purchased an additional 17.83 lakh shares between January 1 and March 3, raising its holding from 4.26% as of […]
Sensex Today | Stock Market LIVE Updates: Nifty support at 22,500 under cloud after Nasdaq sell-off, Asia decline
[ad_1] Sensex Today | Stock Market LIVE Updates: Indian benchmark indices Nifty 50 and Sensex ended the previous trade session little changed. Nifty 50 closed at 22,545.05, while Sensex ended at 74,612.43. Sensex Today | Stock Market LIVE Updates: Nifty 50 ended the previous trade session 3,732.3 points below its record high of 26,277.35. Overnight, […]
Sensex Today | Stock Market LIVE Updates: GIFT Nifty indicates gap-down open; Zomato, Jio Fin in focus
[ad_1] Sensex Today | Stock Market LIVE Updates: Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the red. Nifty 50 closed at 22,795.90, while Sensex ended at 75,311.06. Sensex Today | Stock Market LIVE Updates: Nifty 50 ended the previous trade session 3,481.45 points below its record high of 26,277.35. […]
Granules India Results: Shares slip after Q3 net profit, revenue decline – CNBC TV18
[ad_1] Granules India’s net profit declined 6.4% to ₹117.6 crore compared to ₹125.6 crore in the same quarter last year. Revenue dropped 1.5% to ₹1,137.6 crore, down from ₹1,156 crore a year ago. Company Value Change %Change Meanwhile, EBITDA fell 8% to ₹230.2 crore, with margins narrowing to 20.2% from 22% in the year-ago period. […]
Granules India says new product approval from Gagillapur could be impacted post USFDA action – CNBC TV18
[ad_1] Granules India Ltd. has informed the exchanges that the new product approvals from its crucial Gagillapur facility in Andhra Pradesh could be impacted after the US Food & Drug Administration (USFDA) classified the facility as an Official Action Indicated (OAI) on Tuesday, December 3. Company Value Change %Change “This classification does not impact the […]
Granules India’s loss is which pharma company’s gain? – CNBC TV18
[ad_1] Granules India Ltd.’s shares fell 10% on Tuesday after the USFDA granted an Official Action Indicated (OAI) status to its crucial Gagillapur facility, which had earlier received a form 483 with six observations. Company Value Change %Change An Official Action Indicated or OAI status means that a facility has objectionable conditions or practices that […]
Granules India secures USFDA approval for antidepressant tablets – CNBC TV18
[ad_1] Granules Pharmaceuticals, Inc., a wholly-owned foreign subsidiary of Granules India, has achieved a significant milestone by securing approval from the U.S. Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) of Bupropion hydrochloride extended-release tablets USP (SR). The approved tablets are bioequivalent and therapeutically equivalent to GlaxoSmithKline LLC’s Wellbutrin SR sustained-release […]
Granules India shares fall 8% on concerns over six USFDA observations to the Gagilapur unit – CNBC TV18
[ad_1] The US Food and Drug Administration (USFDA) had issued six observations to Granules India’s Gagillapur facility in Hyderabad, Telangana, following an inspection, which was conducted from August 26 to September 6. CNBC-TV18 has accessed Form 483 issued to Granules’ Gagillapur facility. Here are the key violations identified: – Equipment and utensils not cleaned […]
Granules India gains after arm receives USFDA nod for Glycopyrrolate Oral Solution – CNBC TV18
[ad_1] Granules India Ltd on Tuesday, August 20, announced that its subsidiary Granules Pharmaceuticals, Inc. (GPI) has received United States Food and Drug Administration (USFDA) approval for Glycopyrrolate Oral Solution, used to treat neurological conditions in children. In an exchange filing, the company said its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. (GPI), has been granted […]
Granules India gains after pharma firm gets USFDA nod for antidepressant drug – CNBC TV18
[ad_1] Granules India Ltd shares gained 2.12% to hit an all-time high of ₹666.3 apiece on BSE on Friday, August 9, after the US Food and Drug Administration (USFDA) approved its Abbreviated New Drug Application (ANDA) for Trazodone Hydrochloride Tablets USP. Trazodone tablets are indicated for the treatment of major depressive disorder in adults. In […]